Epstein Secrets

; margin: 5px 0px 10px;">Preliminary efficacy for Pfizer (95%) and Moderna (94.5%) were both found in clin

ying a specific target: </strong>The vaccines for Pfizer and Moderna are targeting the same spike protein

0 0 0 15px; padding: 0px;"><strong>Return of the Merck: </strong>Drugmaker Merck bought OncoImmune, whic

ons Repatriating Dividends Under IRC Section 965, Company Repatriated Amount ($bn) Selected Items, by Selected Major and Minor Industry of the Parent Pfizer 355 Corporation, Tax Years 2004-2006 Merck 15.9 Industry % of Repatriated Cash Dividends Hewlett Packard 145 Pharmaceutical and medicine manufacturin

965, Company Repatriated Amount ($bn) Selected Items, by Selected Major and Minor Industry of the Parent Pfizer 355 Corporation, Tax Years 2004-2006 Merck 15.9 Industry % of Repatriated Cash Dividends Hewlett Packard 145 Pharmaceutical and medicine manufacturing 29% Johnson & Johnson 107 Computer and el

DA & revs inline, raising FY guidance, mainly in Maersk line EFTA00406719 (trading +1.0%) Astrazeneca ups guidance after selling Nexium rights to Pfizer, ups guidance (trading +0.70%) Salzgitter Q2 inline (post profit warning June 26th), leaves outlook unchanged (trading +1.5%) Merck Q2 good beat

um rights to Pfizer, ups guidance (trading +0.70%) Salzgitter Q2 inline (post profit warning June 26th), leaves outlook unchanged (trading +1.5%) Merck Q2 good beat across the board helped by FX, raising guidance (trading +4.2%) Celesio Q2 inline across the board, maintains full year guidance (tradi

its. Gilead, maker of Sovaldi, has profits of around 5o percent. Biogen, Amgen and other biotech firms have profits of around 30 percent. Merck and Pfizer are seeing profits of 18 percent or more. Even if profits were cut by a third or a half, there would be sufficient incentive to assume the risks of

huge profits. Gilead, maker of Sovaldi, has profits of around 5o percent. Biogen, Amgen and other biotech firms have profits of around 30 percent. Merck and Pfizer are seeing profits of 18 percent or more. Even if profits were cut by a third or a half, there would be sufficient incentive to assume th

7/21, Weise, 10.31M) reports in testimony to a US House subcommittee on Tuesday, "executives from AstraZeneca, Johnson & Johnson, Merck, Moderna and Pfizer said their goal is to have effective vaccines available as soon as possible while following all safety and regulatory guidelines." NBC Nightly News

afety. USA Today (7/21, Weise, 10.31M) reports in testimony to a US House subcommittee on Tuesday, "executives from AstraZeneca, Johnson & Johnson, Merck, Moderna and Pfizer said their goal is to have effective vaccines available as soon as possible while following all safety and regulatory guideline

(7/21, Weise, 10.31M) reports in testimony to a US House subcommittee on Tuesday, "executives from AstraZeneca, Johnson & Johnson, Merck, Modema and Pfizer said their goal is to have effective vaccines available as soon as possible while following all safety and regulatory guidelines." NBC Nightly News

2021/5478232002/> (7/21, Weise, 10.31M) reports in testimony to a US House subcommittee on Tuesday, "executives from AstraZeneca, Johnson & Johnson, Merck, Modema and Pfizer said their goal is to have effective vaccines available as soon as possible while following all safety and regulatory guidelines.

, Operation Warp Speed Chief Operating Officer Gen. Gustave Perna said vaccines will be available 24 hours after receiving FDA approval. Perna: "If Pfizer is first, I'll call Pfizer, and they'll begin distributing vaccines. It will go to 64 jurisdictions simultaneously, 50 states, eight territories and

ting an experimental vaccine from Sanofi/GSK and one from startup Novavax, which are expected to begin large trials in the U.S. in the coming weeks. Merck, which has received far less funding, is a few months further behind." Some Countries Face "Immense" Stakes With AstraZeneca's Vaccine. Bloomberg

, Operation Warp Speed Chief Operating Officer Gen. Gustave Perna said vaccines will be available 24 hours after receiving FDA approval. Perna: "If Pfizer is first, I'll call Pfizer, and they'll begin distributing vaccines. It will go to 64 jurisdictions simultaneously, 50 states, eight territories and

ing an experimental vaccine from Sanofi/GSK and one from startup Novavax, which are expected to begin large trials in the U.S. in the coming weeks. Merck, which has received far less funding, is a few months further behind." Some Countries Face "Immense" Stakes With AstraZeneca's Vaccine. Bloomberg (1

7/21, Weise, 10.31M) reports in testimony to a US House subcommittee on Tuesday, "executives from AstraZeneca, Johnson & Johnson, Merck, Moderna and Pfizer said their goal is to have effective vaccines available as soon as possible while following all safety and regulatory guidelines." NBC Nightly News

afety. USA Today (7/21, Weise, 10.31M) reports in testimony to a US House subcommittee on Tuesday, "executives from AstraZeneca, Johnson & Johnson, Merck, Moderna and Pfizer said their goal is to have effective vaccines available as soon as possible while following all safety and regulatory guideline

7/21, Weise, 10.31M) reports in testimony to a US House subcommittee on Tuesday, "executives from AstraZeneca, Johnson & Johnson, Merck, Moderna and Pfizer said their goal is to have effective vaccines available as soon as possible while following all safety and regulatory guidelines." NBC Nightly News

afety. USA Today (7/21, Weise, 10.31M) reports in testimony to a US House subcommittee on Tuesday, "executives from AstraZeneca, Johnson & Johnson, Merck, Moderna and Pfizer said their goal is to have effective vaccines available as soon as possible while following all safety and regulatory guideline